The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.
 
Vincent Chung
Consulting or Advisory Role - Apeiron Biologics; Gritstone Bio; Ipsen; Westwood Bioscience
Speakers' Bureau - Celgene; Ipsen
Research Funding - Merck (Inst); Roche (Inst)
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BluePrint Medicines; Bristol-Myers Squibb; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Synthon; Taiho Pharmaceutical
Research Funding - ADC Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; CerRx; FORMA Therapeutics; Medtronic; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - 7 Hills Pharma; AADi; Aeglea Biotherapeutics; Agenus; AiMed; AlaMab Therapeutics; Alpha Cancer Technologies; Apeiron Biologics; Aptose Biosciences; Array BioPharma; Arvinas; Athenex; Avesta76 Therapeutics; Axis Therapeutics; Bessor Pharma; BiolineRx; BioXCel therapeutics; Bryologyx; CanBas; Cancer Prevention Pharmaceuticals; Codiak Biosciences; Coordination Pharmaceuticals; Corcept Therapeutics; CV6 Therapeutics; Decoy Biosystems; DNAtrix; DrugCendR; EMD Serono; Erimos Pharmaceuticals; Esperance Pharmaceuticals; EXACT Therapeutics; Five Prime Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; GiraFpharma; Helix BioPharma; HUYA Bioscience International; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; Kelun; Kura Oncology; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Lycia Therapeutics; MaveriX Oncology; Medical Prognosis Institute; NeoTx; NGM Biopharmaceuticals; Nirogy Therapeutics; Northern Biologics; Novita Pharmaceuticals; Noxxon Pharma; Nucana; Oncology Venture; Oncolyze; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; RadImmune; Reflexion Medical; Reglagene; RenovoRx; Samumed; Seagen; Senhwa Biosciences; Sirnaomics; SOBI; SOTIO; Strategia Therapeutics; Synergene; TD2; Tolero Pharmaceuticals; TP Therapeutics; Varian Biopharma; Verily; Vicus Therapeutics; Viracta Therapeutics; Xerient; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Xin-Yun Huang
Employment - Novita Pharmaceuticals (I)
Leadership - Novita Pharmaceuticals; Novita Pharmaceuticals (I)
Stock and Other Ownership Interests - Novita Pharmaceuticals; Novita Pharmaceuticals (I)
Consulting or Advisory Role - Novita Pharmaceuticals
Research Funding - Novita Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Novita has licensed a technology from Cornell University, and Cornell receives milestone payments from Novita. (Inst); Novita has licensed a technology from Cornell University, and Cornell receives milestone payments from Novita. I am a co-inventor on the patents and receive milestone payments from Cornell.
Travel, Accommodations, Expenses - Novita Pharmaceuticals (I)
 
Edward Graeme Garmey
Stock and Other Ownership Interests - Cerulean Pharma
Consulting or Advisory Role - Novita Pharmaceuticals
 
Jillian Zhang
Employment - Novita Pharmaceuticals
Leadership - Novita Pharmaceuticals
Stock and Other Ownership Interests - Novita Pharmaceuticals
Consulting or Advisory Role - Novita Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - Novita Pharmaceuticals (I)
 
Frank Yung-Chin Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aptitude Health; Tempus
Patents, Royalties, Other Intellectual Property - Clinical trial software.